References
- Centers for Disease Control and Prevention. Update: AIDS among women—United States, 1994. MMWR 1995; 44(5): 81–4 [Erratum, MMWR 1995;44(7): 135]
- Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, and prevalence—United States, 1996. MMWR 1997; 46(8): 165–73
- Connor EM, Sperling RS, Gelber T, et al, for the Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331 (18): 1173–80
- Royce RA, Sena A, Cates W Jr, et al. Sexual transmission of HIV. N Engl J Med 1997; 336(15): 1072–8
- Larkin J, Ison MG, Toney J, et al. Recognizing HIV in women. Infect Med 1997 Feb: 124–141
- Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection: The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994; 272(24): 1915–21
- Schwebke KE, Hoyt LG. HIV infection in women and children. Minn Med 1995; 78(11): 35–9
- Centers for Disease Control and Prevention. HIV/AIDS surveillance report. MMWR 1996; 8(2): 1–39
- Centers for Disease Control and Prevention. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR 1995; 44(RR-7): 1–15
- Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994; 43(RR-11): 1–20
- Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996; 275(19): 1483–8
- Wilfert CM. Prevention of perinatal transmission of human immunodeficiency virus: a progress report 2 years after completion of AIDS Clinical Trials Group trial 076. Clin Infect Dis 1996: 23(3): 438–41
- Pitt J, Brambilla D, Reichelderfer P, et al. Maternal immunologie and virologie risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. J Infect Dis 1997; 175(3): 567–75
- Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335(22): 1621–9
- Mofenson LM. A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus. Pediatr Infect Dis J 1995; 14(3): 169–76
- Bryson YJ. Perinatal HIV-1 transmission: recent advances and therapeutic interventions. AIDS 1996; 10(Suppl 3): 33–42S
- Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol 1997; 176(2): 478–89
- Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43(RR-12): 1–11
- Centers for Disease Control and Prevention. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995; 44(RR-4): 1–11